Bayer, Bristol-Myers Squibb and Ono Pharma Team on Colorectal Cancer

MARK TERRY | July 18, 2019

article image
Bayer, Bristol-Myers Squibb and Ono Pharmaceutical have teamed up to study the most common type of metastatic colorectal cancer (mCRC). The three companies will collaborate to test Bayer’s kinase inhibitor Stivarga (regorafenib) and Bristol-Myers Squibb’s and Ono’s anti-PD-1 checkpoint inhibitor Opdivo (nivolumab) in microsatellite stable metastatic colorectal cancer (MSS mCRC). The effectiveness of immuno-oncology treatments for some subpopulations of CRC have been observed, but about 95% of mCRC have MSS tumors, where immuno-oncology monotherapies haven’t been as effective.

Spotlight

Health Quest

Health Quest is a growing multi-hospital system encompassing the award-winning facilities of Vassar Brothers Medical Center (Poughkeepsie, NY), Northern Dutchess Hospital (Rhinebeck, NY), Putnam Hospital Center (Carmel, NY), Sharon Hospital (Sharon, CT) and multi-specialty group Health Quest Medical Practice, P.C., as well as an extensive network of affiliated sites of care. Health Quest is transforming healthcare.

OTHER ARTICLES

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | April 11, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 3, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

How pharma can continue engaging HCPs in a world gripped by COVID-19

Article | April 10, 2020

Medscape is the leading source of clinical news, health information, and point-of-care tools for healthcare professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses and other educational programmes for physicians, nurses, and other healthcare professionals. Both Medscape and Medscape Education are part of WebMD Health Corp., an Internet Brands company. Face-to-face interactions between pharma and physicians have essentially ceased overnight during the COVID-19 pandemic, but that doesn’t mean HCPs have stopped looking for new medical information.

Read More

Spotlight

Health Quest

Health Quest is a growing multi-hospital system encompassing the award-winning facilities of Vassar Brothers Medical Center (Poughkeepsie, NY), Northern Dutchess Hospital (Rhinebeck, NY), Putnam Hospital Center (Carmel, NY), Sharon Hospital (Sharon, CT) and multi-specialty group Health Quest Medical Practice, P.C., as well as an extensive network of affiliated sites of care. Health Quest is transforming healthcare.

Events